Web search keywords can help spot early Alzheimer’s cases
16/01/2020Researchers from MOPEAD tested different ways to engage patients, including reaching out to suspected early Alzheimer’s sufferers by flagging internet searches like “forgetfulness”
Newsroom
What patients really want: "Nothing about us without us”
09/01/2020Drug-makers have only recently started to give drug-takers a say in how their medicines are made, turning patients into a new generation of experts.
PET scans that show brain changes caused by Alzheimer’s give doctors confidence in diagnosis
20/12/2019Being able to visualise the pathology linked to the disease is a big benefit for diagnosis and patient management. Researchers from an IMI project that set out to get definitive data on the role of amyloid PET scans in Alzheimer’s disease diagnosis are hearing from physicians that being able to visualise the underlying pathology linked to the disease is a big benefit for diagnosis and patient management. The ability to...
Sign up for the IMI2 – Call 20 webinars
17/12/2019IMI2 – Call 20 will be launched in January 2020 and features topics on cancer, tuberculosis, psoriasis, drugs based on proteins, and vaccines. Registration is now open for the IMI2 - Call 20 webinars, which will be held from 22 to 31 January 2020 inclusive. Registration is free but obligatory via the webinar page. There are webinars on all Call topics as well as IMI's rules and procedures and opportunities...
Cache of research materials on understudied proteins now available to scientific community
12/12/2019The RESOLUTE project have made the DNA reagents for 446 solute carriers freely available in the hope that the proteins might be used as targets in drug development
Alzheimer’s project EPAD releases first wave of data to research community
12/12/2019The data comes from EPAD’s study into the earliest stages of Alzheimer’s dementia – before symptoms appear.
Alzheimer's researchers use AI to get access to brains
10/12/2019The Aetionomy project used digital technology to study brains without needing samples from living people, allowing them to simulate processes associated with Alzheimer's.
How competition nearly killed Alzheimer’s research
06/12/2019Repeat failures put the brakes on research until the pharma industry regrouped in a new, non-competitive, way.
Genetically engineered antibodies cut infection rates in a trial. Could they wean us off antibiotics?
04/12/2019Researchers’ hopes are raised after a trial using monoclonal antibodies to prevent pneumonia in ventilated intensive care patients gets good results
IMI research gets cited at double the global average rate
27/11/2019Report shows rise in performance, with IMI research cited 60% more than EU average and twice as much as the rest of the world.
Can real world data replicate a clinical trial? EHDEN study suggests yes
26/11/2019IMI’s EHDEN project dramatically demonstrated the power of using clinical data in research by replicating, during a five-day ‘study-a-thon’, the results of a systematic review covering 20 years of research, and a multi-year clinical trial.
New IMI project 3TR to advance personalised treatments for immune diseases
25/11/20193TR hopes to unravel the mystery of why treatments don't work in some patients.
Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
21/11/2019Quick tests for bacterial infections are out there, but insurers won’t cover them and doctors are reluctant to use them.
Trials@Home project brings clinical trials to the patient
21/11/2019In the future, patients could take part in clinical trials from the comfort of their own home, avoiding the inconvenience of regular clinic visits.
How can we make clinical trials more kid-friendly?
20/11/2019IMI-funded researchers are inviting children and young people to help decide how clinical trials with child participants should be run.
A very promising new antibiotic just started clinical trials
19/11/2019Researchers from ENABLE are hopeful about apramycin because it has passed the stage at which most potential antibiotics fail.
Why it’s so hard to make new antibiotics
15/11/2019There’s no lack of chemicals that can kill bacteria. One of the main reasons there have been so few new antibiotics developed in recent decades – apart from a poor return on investment – is that researchers have run out of ideas on how to outwit the protective mechanisms of Gram-negative bacteria.
For small companies, IMI projects can help tap into new markets
11/11/2019CEO of TRISTAN project partner tells IMI about the opportunities that can open up as a result of getting involved in an IMI project. Karin von Wachenfeldt, Ph. D. is the CEO of Truly Labs, a Swedish SME that carries out preclinical research. Tell us about your company: Truly Labs is a small preclinical CRO (contract research organisation) that provides lab services for drug development. We are based in Lund...
New antibiotics won’t stop antimicrobial resistance. Luckily, there are other things we can try
05/11/2019Vaccines could offer hope - but who to vaccinate, and against what, has no clear answer yet. By Pierre Meulien, Director, IMI
Focus: Antimicrobial resistance
04/11/2019Antimicrobial resistance is becoming one of the defining problems of our time. As bacteria become resistant to the drugs that are supposed to kill them, scientists, policy makers and the pharma industry are looking at different ways to fix the problem before it’s too late. IMI has invested heavily in AMR research. To date, we have invested almost €800 million on 14 projects. In November, we will be taking a...
New IMI project puts immune cells in the spotlight
04/11/2019EUR 27 million Immune-Image project will advance the use of imaging technologies to track immune cells. Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The 5-year Immune-Image project, which started recently, aims to pioneer the...
Trial of second Ebola vaccine to start in Democratic Republic of the Congo
31/10/2019The trial of the two-dose Ebola vaccine regimen aims to help tackle the current outbreak and strengthen future Ebola epidemic preparedness. An international consortium will soon start a large-scale clinical trial of an Ebola vaccine regimen in the Democratic Republic of the Congo (DRC), which is currently experiencing the second worst Ebola epidemic in history. IMI has contributed significantly to the development of the two-dose vaccine regimen, which is manufactured by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Meet IMI at BIO-Europe 2019
29/10/2019In two weeks’ time, IMI will be in Hamburg for BIO-Europe 2019, which runs from 11 to 13 November. A highlight for IMI will be a session on the morning of 12 November on EU support for small and medium-sized enterprises (SMEs). Among the speakers is IMI’s Magali Poinot, who will explain the benefits for SMEs of participating in IMI projects and show how SMEs can get involved in IMI...
Project to team up with African manufacturer to make diagnostic tests
28/10/2019This project is trying out a different kind of capacity building. Apart from hosting workshops and info sessions on the use of VHFMoDRAD's diagnostic tests, the project plans to identify and team up with a Senegalese producer that can make the tests themselves.
Spotlight on early-career investigators: an interview with Benjamin Falcon
23/10/2019Benjamin Falcon is a scientist in the IMPRiND project, which is investigating the role of misfolded proteins in Alzheimer’s and Parkinson’s diseases. Dr Benjamin Falcon is a postdoctoral scientist at the UK Medical Research Council Laboratory of Molecular Biology, working to untangle the mysteries of neurodegenerative conditions such as Alzheimer’s disease. He completed his PhD with Professor Michel Goedert and has developed an impressive track record of findings that progress...
Contribute to the research agenda of the new health PPP
23/10/2019Have your say on the strategic research agenda for a public-private partnership for health innovation under Horizon Europe.
Good data on medication safety for new and expectant mothers is overdue
18/10/2019A survey intends to get a clear picture of women’s experiences of medicating while pregnant or breast-feeding Video: Caroline Swain was five weeks pregnant when she was diagnosed with breast cancer. Her health providers didn't initially know what treatments she could take. © The Pregnancy and Medicines Initiative The problem Evidence suggests that up to 95% of the five million women who get pregnant in the EU every year will...
As Ebola rages in the DRC, the world is closer than ever to the first licensed vaccine
17/10/2019IMI contributed to development of the most promising Ebola vaccines, helping to bring them closer to regulatory approval
Find out about IMI’s future funding opportunities
15/10/2019Cancer, tuberculosis, and psoriasis are among the topics that could be part of our next Call for proposals, IMI2 – Call 20. Also slated for inclusion in the Call are topics on drugs based on proteins, and vaccines.
How do you prepare for a pandemic?
10/10/2019IMI Director Pierre Meulien talks about IMI's reaction to the biggest Ebola outbreak in history and how the world is better prepared for future major epidemics.
EUPATI patient expert training course is open for enrolment
08/10/2019Applications are now being accepted for EUPATI's 14-month training course for laypeople on medicines research and development.
Data-driven personalised care for Alzheimer's patients
07/10/2019EU and industry-funded researchers are testing wearable devices, Internet of Things technologies and smartphone apps to transform the lives of people with Alzheimer's disease.
Focus on: Ebola
03/10/2019During the month of October we will be taking a look at some of the results of our Ebola-related research projects.
Two genes singled out as significant in the development of Alzheimer's
01/10/2019The PHAGO project has identified two genes that might have a significant impact on Alzheimers disease development and progression.
Ebola can now be detected in 15 minutes. Here’s how the diagnostics tests work
30/09/2019IMI backed three bedside Ebola detection tests that work quickly with minimal equipment or training.